Patents by Inventor Fasseli Joseph Coulibaly

Fasseli Joseph Coulibaly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10294280
    Abstract: A fusion protein comprising an N-terminal portion and a C-terminal portion, wherein the N-terminal portion is a heterologous protein of interest which includes membrane proteins and antigens and the C-terminal portion is a polyhedrin targeting peptide which is derived from cypovirus polyhedrin and binds to cypovirus polyhedrin. The polyhedrin targeting peptide is described as a C-terminal portion of cypovirus polyhedrin and as C-terminal portion of cypovirus polyhedrin absent all or part of the N-terminal H1 helix sequence. Vectors and cells capable of expressing the fusion proteins are also provided. The fusion proteins fold with cypovirus polyhedrin to form modified complexes, polyhedra/microcubes useful in myriad applications, including as a platform technology for prophylactic or therapeutic vaccinations, therapeutics and diagnostics, including vaccines, therapeutics and diagnostics etc. employing membrane proteins.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 21, 2019
    Assignee: Monash University
    Inventor: Fasseli Joseph Coulibaly
  • Publication number: 20170204143
    Abstract: A fusion protein comprising an N-terminal portion and a C-terminal portion, wherein the N-terminal portion is a heterologous protein of interest which includes membrane proteins and antigens and the C-terminal portion is a polyhedrin targeting peptide which is derived from cypovirus polyhedrin and binds to cypovirus polyhedrin. The polyhedrin targeting peptide is described as a C-terminal portion of cypovirus polyhedrin and as C-terminal portion of cypovirus polyhedrin absent all or part of the N-terminal H1 helix sequence. The polyhedrin targeting peptide may also be derived from silkworm cypovirus (BmCPV) polyhedrin. In one example, the polyhedrin targeting peptide comprises the peptide sequence set forth in SEQ ID NO: 14, SEQ ID NO:13 or SEQ ID NO:12 or a functional variant thereof. Vectors and cells capable of expressing the fusion proteins are also provided.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 20, 2017
    Inventor: Fasseli Joseph Coulibaly
  • Publication number: 20170000878
    Abstract: A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (CPV). Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto. Methods of using same to elicit an immune response.
    Type: Application
    Filed: August 9, 2016
    Publication date: January 5, 2017
    Inventors: Fasseli Joseph COULIBALY, Ashley Scott MANSELL, Rosemary Ann FFRENCH
  • Patent number: 8554493
    Abstract: Cypoviruses and baculoviruses are notoriously difficult to eradicate because the virus particles are embedded in micron-sized protein crystals called polyhedra. The remarkable stability of polyhedra means that like bacterial spores these insect viruses remain infectious for years in soil. Although these unique in vivo protein crystals have been extensively characterized since the early 1900s, their atomic organization remains elusive. Here we describe the 2 crystal structure of both recombinant and infectious silkworm cypovirus polyhedra determined using 5-12 micron crystals purified from insect cells. These are the smallest crystals yet used for de novo X-ray protein structure determination. It was found that polyhedra are made of trimers of the viral polyhedrin protein and contain nucleotides. Although the shape of these building blocks is reminiscent of some capsid trimers, polyhedrin has a new fold and has evolved to assemble in vivo into 3-D cubic crystals rather than icosahedral shells.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: October 8, 2013
    Assignees: National University Corporation Kyoto Institute of Technology, Protein Crystal Corporation
    Inventors: Peter Metcalf, Fasseli Joseph Coulibaly, Hajime Mori, Norio Hamada, Keiko Ikeda, Yui Lam Elaine Chiu, Hiroshi Ijiri
  • Publication number: 20130171129
    Abstract: A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (CPV), Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto. Methods of using same to elicit an immune response.
    Type: Application
    Filed: June 23, 2011
    Publication date: July 4, 2013
    Inventors: Fasseli Joseph Coulibaly, Ashley Scott Mansell, Rosemary Ann Ffrench
  • Publication number: 20100216651
    Abstract: Cypoviruses and baculoviruses are notoriously difficult to eradicate because the virus particles are embedded in micron-sized protein crystals called polyhedra. The remarkable stability of polyhedra means that like bacterial spores these insect viruses remain infectious for years in soil. Although these unique in vivo protein crystals have been extensively characterized since the early 1900s, their atomic organization remains elusive. Here we describe the 2 crystal structure of both recombinant and infectious silkworm cypovirus polyhedra determined using 5-12 micron crystals purified from insect cells. These are the smallest crystals yet used for de novo X-ray protein structure determination. It was found that polyhedra are made of trimers of the viral polyhedrin protein and contain nucleotides. Although the shape of these building blocks is reminiscent of some capsid trimers, polyhedrin has a new fold and has evolved to assemble in vivo into 3-D cubic crystals rather than icosahedral shells.
    Type: Application
    Filed: February 28, 2008
    Publication date: August 26, 2010
    Applicants: National University Corporation Kyoto Institute of Technology, Protein Crystal Corporation
    Inventors: Peter Metcalf, Fasseli Joseph Coulibaly, Hajime Mori, Norio Hamada, Keiko Ikeda, Yui Lam Elaine Chiu, Hiroshi Ijiri